Mizuho Securities USA LLC Buys 16,838 Shares of Edwards Lifesciences Co. (NYSE:EW)

Mizuho Securities USA LLC boosted its stake in Edwards Lifesciences Co. (NYSE:EW) by 43.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 55,900 shares of the medical research company’s stock after acquiring an additional 16,838 shares during the quarter. Mizuho Securities USA LLC’s holdings in Edwards Lifesciences were worth $4,138,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in EW. Harbor Capital Advisors Inc. boosted its stake in Edwards Lifesciences by 2.5% during the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock worth $824,000 after acquiring an additional 273 shares in the last quarter. Nordea Investment Management AB boosted its stake in Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after acquiring an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its stake in Edwards Lifesciences by 6.7% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock worth $355,344,000 after acquiring an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC bought a new position in Edwards Lifesciences during the fourth quarter worth $3,702,000. Finally, Avanza Fonder AB bought a new position in Edwards Lifesciences during the fourth quarter worth $4,845,000. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

EW has been the topic of several research analyst reports. Truist Financial reissued a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. The Goldman Sachs Group raised their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Barclays raised their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Piper Sandler raised their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average target price of $79.95.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 400 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the transaction, the vice president now owns 22,588 shares of the company’s stock, valued at approximately $1,569,414.24. The trade was a 1.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now directly owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 51,303 shares of company stock worth $3,715,776 over the last quarter. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $70.46 on Monday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a 50-day simple moving average of $71.42 and a 200 day simple moving average of $70.38. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market capitalization of $41.42 billion, a PE ratio of 10.11, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.